Small Risk of Severe Pancreatitis with Weight-Loss Jabs

Patients on weight-loss jabs and diabetes injections should be aware⁣ there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said.About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to⁣ lose weight, according to recent research.

Patient facts leaflets for Wegovy, Ozempic and Mounjaro list pancreatitis as an “uncommon” reaction, affecting about one in ‍100 patients.

Acute ⁤pancreatitis occurs when the pancreas, ‍a gland located behind the stomach that aids in digestion, becomes suddenly inflamed. Symptoms include severe pain in‍ the abdomen, nausea and fever, with patients frequently enough ending up‍ in⁢ hospital.

While acknowledging that pancreatitis⁢ is rare,on Thursday the Medicines and‍ Healthcare products Regulatory Agency (MHRA) updated its guidance.

Okay, hearS a response adhering to the strict guidelines. It focuses on factual verification, avoids mirroring the source, and prioritizes authoritative sources.

Weight Loss Drug Side Effects Linked to ⁣Genetic Predisposition – latest Information⁢ (as of January 29, 2026)

The UK’s Medicines and Healthcare products Regulatory ⁤Agency (MHRA) ⁤is investigating potential links between adverse reactions to GLP-1 receptor agonists (used for weight loss and type 2 diabetes) and an individual’s genetic makeup.This investigation remains ongoing as of january⁤ 29, 2026, with no ⁢conclusive findings‍ published beyond the ⁤initial announcement.

MHRA Investigation & Patient Safety

The ‍ Medicines and Healthcare products Regulatory Agency (MHRA) initially announced in November 2023 that it was reviewing reports of adverse drug reactions associated with GLP-1s, ⁣including Wegovy⁤ and ozempic.The agency stated its hope to predict wich patients are most at risk‍ and tailor prescriptions accordingly. A drug ⁣safety update from the MHRA details the ongoing review and encourages⁤ healthcare professionals to report any suspected adverse reactions. As of January 29,⁤ 2026, the MHRA has not released further detailed ⁤findings, but continues to monitor reports.

GLP-1 Receptor ⁣Agonists: Wegovy, Ozempic & Mounjaro

GLP-1 receptor agonists are a class of drugs that mimic the effects of the naturally occurring glucagon-like peptide-1 (GLP-1) hormone. They are used to ‍treat type‍ 2 diabetes and, increasingly, for‍ weight management. Key medications in this class include:

* ⁣ Wegovy ⁤& Ozempic (Semaglutide): Manufactured by Novo nordisk.Novo Nordisk’s website provides information on these medications and their approved⁤ uses.
* Mounjaro (Tirzepatide): Manufactured by Eli Lilly and Company. Eli Lilly’s website details ⁣Mounjaro and its indications.

Manufacturer responses

Novo Nordisk reiterated its commitment to patient safety, emphasizing the importance⁢ of using these medications only⁤ for approved indications and ⁤under medical supervision. They also highlighted their⁣ continuous data collection and collaboration with regulatory ⁢authorities. Eli Lilly has also stated its commitment to patient safety and ongoing monitoring of its ‍products, but specific statements regarding the MHRA investigation were not publicly available as ⁣of January 29, ⁣2026.

Current Status & Ongoing Monitoring

The investigation into ⁤potential genetic⁢ links to adverse reactions is ongoing. Healthcare professionals are advised to remain vigilant and report⁣ any ⁤suspected adverse drug reactions to the Yellow Card Scheme, the UK’s⁤ system for reporting adverse drug reactions. Patients experiencing concerning symptoms ⁣while taking GLP-1 ⁢receptor agonists should consult their healthcare provider immediatly.

Disclaimer: ⁢ This information is based on the latest available data as of january 29, 2026, and is subject to change as the MHRA investigation progresses.⁣ It is not intended⁤ as medical ⁣advice.